ATAI trades 131.2% below Wall Street's consensus target of $12.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ATAI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Atai Beckley N.V (ATAI) has a Wall Street consensus price target of $12.00, based on estimates from 4 covering analysts. With the stock currently trading at $5.19, this represents a potential upside of +131.2%. The company has a market capitalization of $1.91B.
Analyst price targets range from a low of $10.00 to a high of $15.00, representing a 42% spread in expectations. The median target of $11.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ATAI trades at a trailing P/E of -1.8x. Analysts expect EPS to grow +85.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
CMPSCOMPASS Pathways plc | $1.2B | $12.99 | $18.57 | +43.0% | Buy | — | 13 |
MNMDMind Medicine (MindMed) Inc. | $2.0B | $20.69 | $20.00 | -3.3% | Buy | — | 1 |
CYBNCybin Inc. | $304M | $6.09 | — | — | Buy | — | 4 |
SILOSilo Pharma, Inc. | $5M | $5.66 | — | — | — | — | — |
ENVBEnveric Biosciences, Inc. | $865667 | $1.45 | — | — | — | — | — |
JAZZJazz Pharmaceuticals plc | $15.5B | $247.72 | $257.44 | +3.9% | Buy | 9.8x | 48 |
INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
PRAXPraxis Precision Medicines, Inc. | $9.4B | $323.95 | $589.00 | +81.8% | Buy | — | 16 |
ACADACADIA Pharmaceuticals Inc. | $4.5B | $26.20 | $34.38 | +31.2% | Buy | 68.9x | 37 |
AXSMAxsome Therapeutics, Inc. | $12.9B | $249.76 | $262.38 | +5.1% | Buy | — | 26 |
Quick answers to the most common questions about buying ATAI stock.
The consensus Wall Street price target for ATAI is $12, representing 131.2% upside from the current price of $5.19. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ATAI has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $12 implies 131.2% upside from current levels.
ATAI's current price is $5.19 with a consensus target of $12 (131.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $15 for ATAI, while the most conservative target is $10. The consensus of $12 represents the median expectation. These targets typically reflect 12-month expectations.
ATAI is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ATAI stock forecast based on 4 Wall Street analysts shows a consensus price target of $12, with estimates ranging from $10 (bear case) to $15 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ATAI, with a "Buy" consensus rating and $12 price target (131.2% upside). 4 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ATAI analyst price targets range from $10 to $15, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.